CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the most profitable new stocks to buy now. On July 18, it was reported that ...

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Pembrolizumab, an anti–programmed death 1 (PD-1) monoclonal antibody, is a cornerstone of first-line standard care for recurrent and metastatic HNSCC. 1,2,7 The addition of pembrolizumab to ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.

Pembrolizumab is also approved as first-line treatment in cisplatin-ineligible patients with high PD-L1 expression. 9 - 11 Integrating short courses of pre-RC immunotherapy in nonmetastatic MIBC has ...